DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Stalevo (Carbidopa / Levodopa / Entacapone) - Summary

 
 



STALEVO SUMMARY

Stalevo is a combination of carbidopa, levodopa, and entacapone for the treatment of Parkinson's disease.

Stalevo, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) is indicated for the treatment of Parkinson's disease.

Stalevo can be used:

  • To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.
  • To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias.

See all Stalevo indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Virtually reality simplifies early diagnosis of multiple sclerosis and Parkinson's disease
Source: Multiple Sclerosis News From Medical News Today [2016.09.05]
Scientists from Tomsk Polytechnic University and Siberian State Medical University are developing an early diagnosis system for neurodegenerative disorders.

Experimental Test Detects Parkinson's Disease Earlier
Source: MedicineNet Creutzfeldt-Jakob Disease Specialty [2016.08.30]
Title: Experimental Test Detects Parkinson's Disease Earlier
Category: Health News
Created: 8/29/2016 12:00:00 AM
Last Editorial Review: 8/30/2016 12:00:00 AM

Parkinson's Disease
Source: MedicineNet Amyotrophic Lateral Sclerosis Specialty [2016.08.09]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/9/2016 12:00:00 AM

Cancer Drug Shows Early Promise for Parkinson's Disease
Source: MedicineNet Tremor Specialty [2016.07.13]
Title: Cancer Drug Shows Early Promise for Parkinson's Disease
Category: Health News
Created: 7/12/2016 12:00:00 AM
Last Editorial Review: 7/13/2016 12:00:00 AM

Parkinson's Disease: Symptoms, Causes, Stages, and Treatment
Source: MedicineNet Tremor Specialty [2016.06.01]
Title: Parkinson's Disease: Symptoms, Causes, Stages, and Treatment
Category: Slideshows
Created: 8/16/2011 6:25:00 PM
Last Editorial Review: 6/1/2016 12:00:00 AM

more news >>

Published Studies Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. [2009.03.15]
The purpose of this study to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study...

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
OBJECTIVES: Levodopa is effective in the treatment of restless legs syndrome (RLS). However, due to the short duration of action of conventional levodopa/decarboxylase inhibitor formulations, multiple dosing may be required in individual patients with persisting symptoms. We assessed whether a new levodopa formulation containing levodopa, carbidopa, and entacapone (LCE) improves levodopa action in RLS... CONCLUSIONS: Single doses of LCE tablets decreased PLMs in a dose-related manner in RLS patients. Prolonged effects of levodopa on PLMs suggest that, compared with standard levodopa, this new levodopa formulation provides longer symptom control throughout the night in patients with previously untreated RLS.

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo (levodopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess/Comtan)...

Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED. [2011.02.20]
The aim of the study was the development of analytical methods suitable for the quantification of L-dopa, carbidopa and entacapone in plasma of Parkinsonian patients treated with Stalevo((R)). The metabolite 3-O-methyldopa was also determined to obtain some indications on the pharmacokinetics of L-dopa...

[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off]. [2010.07.30]
In Stalevo tablets, used in the therapy of patients with Parkinson's disease, levodopa is combined with decarboxylase inhibitors and COMT inhibitors to provide a more steady plasma concentration of levodopa. Previously several study has shown, that the better pharmacokinetic profile decreases the fluctuation of motor and non-motor symptoms...

more studies >>

Clinical Trials Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Clock and Narcolepsy Genetic Variants and the Effects of Stalevo´┐Ż (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease [Active, not recruiting]
The purpose of this study is to investigate the genetic variants of clock and narcolepsy genes that determine the therapeutic effects of Stalevo« on the quality of sleep in patients with Parkinson's Disease.

Levodopa Concentration Profile With Stalevo 75/125 mg [Completed]
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels. Therefore, it is anticipated that when lower dose of Stalevo is administered after the first higher dose of Stalevo, this would result in equally high levodopa maximum concentration values (Cmax) after each dose throughout the day compared to Cmax after the first dose.

Study to Evaluate Initiation of Stalevo in Early Wearing-off [Completed]
An open, non-randomised, multinational, multicentre direct switch study in levodopa-treated Parkinson's disease patients suffering from early wearing-off in Parkinson's disease. The study will consist of 2 consecutive periods: screening period and study treatment period. Duration of the study will be up to 8 weeks for each subject. The study treatment dosage will be determined by the subject's current, separately administered standard levodopa/DDCI treatment (3-4 doses per day, maximum of total daily dose of 600 mg levodopa) which will be switched to an equivalent dose of Stalevo® without changing the number of doses per day. The levodopa daily dose during Stalevo® treatment may be adjusted according to the study subject's clinical response.

Stalevo in Early Wearing-Off Patients [Completed]
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.

Pharmacokinetic Study With Repeated Doses of Stalevo [Completed]
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.

more trials >>


Page last updated: 2016-09-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015